Sandoz’s Carol Lynch, Global Head Biopharmaceuticals is recognized in a Top 100 list, as the eighth most influential individual in medicine making.
Holzkirchen, 29 April, 2016. Sandoz’s Carol Lynch, Global Head Biopharmaceuticals, has been named as one of the most influential people involved in bringing medicines to patients by Medicine Maker – a leading international publication focused on drug development. Lynch was recognized as the eighth most influential in a Top 100 list that includes some of the most prominent and inspirational individuals involved in medicine making today.
Nominations were proposed by the publication’s readers and ranked by an expert judging panel. Individuals in the Top 100 list come from all avenues of medicine making, whether they are researchers, formulators, manufacturing technicians, marketers or business leaders involved in development of small molecules to biologics or precision medicines for example.
About Carol Lynch
Lynch leads a 3000+ person organization focused on the development, manufacturing and commercialization of biosimilars. She is also responsible for Sandoz’s biopharmaceutical contract manufacturing business. Lynch has more than 25 years of global pharmaceutical and generics industry experience. Prior to joining Sandoz in 2014, Lynch held several Commercial and Development leadership positions in Novartis Pharmaceuticals both globally and in country organizations, including the United States. She is a member of the Sandoz Executive Committee, and Chair of the European Biosimilars Group, a Medicines for Europe sector group.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.